MiR-455 targeting SOCS3 improve liver lipid disorders in diabetic mice

References

• Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights[J]. Science. 2011;332(6037):1519–1523.
   PubMed Web of Science ®Google Scholar
• Wang W, Xu AL, Li ZC, et al. Combination of probiotics and salvia miltiorrhiza polysaccharide alleviates hepatic steatosis via gut microbiota modulation and insulin resistance improvement in high fat-induced NAFLD mice[J]. Diabetes Metab J. 2019;43:e69.
   Google Scholar
• Gan L, Meng ZJ, Xiong RB, et al. Green tea polyphenol epigallocatechin-3-gallate ameliorates insulin resistance in non-alcoholic fatty liver disease mice[J]. Acta Pharmacol Sin. 2015;36(5):597–605.
   PubMed Web of Science ®Google Scholar
• Mcpherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis & clinical management.[J]. J Hepatol. 2015;62(5):1148–1155.
   PubMed Web of Science ®Google Scholar
• Yoon H. Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease[J]. World J Hepatol. 2014;6(11):800.
   PubMedGoogle Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell. 2004;116(2):281–297.
   PubMed Web of Science ®Google Scholar
• Gebert L, Macrae IJ. Regulation of microRNA function in animals[J]. Nat Rev Mol Cell Biol. 2019;20(1):21–37.
   PubMed Web of Science ®Google Scholar
• Lee CH, Kim JH, Lee SW. The role of MicroRNA in pathogenesis and as markers of HCV chronic infection[J]. Curr Drug Targets. 2017;18(7):756–765.
   PubMed Web of Science ®Google Scholar
• Zhang H, Guan M, Townsend KL, et al. MicroRNA-455 regulates brown adipogenesis via a novel HIF1an-AMPK-PGC1alpha signaling network[J]. EMBO Rep. 2015;16(10):1378–1393.
   PubMed Web of Science ®Google Scholar
• Li YJ, Ping C, Tang J, et al. MicroRNA-455 suppresses non-small cell lung cancer through targeting ZEB1[J]. Cell Biol Int. 2016;40(6):621–628.
   PubMed Web of Science ®Google Scholar
• Mao QD, Zhang W, Zhao K, et al. MicroRNA-455 suppresses the oncogenic function of HDAC2 in human colorectal cancer[J]. Braz J Med Biol Res. 2017;50(6):e6103.
   PubMed Web of Science ®Google Scholar
• Xiang S, Dong NG, Liu JP, et al. Inhibitory effects of suppressor of cytokine signaling 3 on inflammatory cytokine expression and migration and proliferation of IL-6/IFN-gamma-induced vascular smooth muscle cells[J]. J Huazhong Univ Sci Technolog Med Sci. 2013;33(5):615–622.
   PubMedGoogle Scholar
• Li Y, Luo T, Wang L, et al. MicroRNA-19a-3p enhances the proliferation and insulin secretion, while it inhibits the apoptosis of pancreatic beta cells via the inhibition of SOCS3[J]. Int J Mol Med. 2016;38(5):1515–1524.
   PubMed Web of Science ®Google Scholar
• Xu L, Li Y, Yin L, et al. miR-125a-5p ameliorates hepatic glycolipid metabolism disorder in type 2 diabetes mellitus through targeting of STAT3[J]. Theranostics. 2018;8(20):5593–5609.
   PubMed Web of Science ®Google Scholar
• Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes[J]. Hepatology. 2014;59(2):713–723.
   PubMed Web of Science ®Google Scholar
• Wang B, Chandrasekera PC, Pippin JJ. Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes[J]. Curr Diabetes Rev. 2014;10(2):131–145.
   PubMedGoogle Scholar
• Sanches SC, Ramalho LN, Augusto MJ, et al. Nonalcoholic steatohepatitis: a search for factual animal models[J]. Biomed Res Int. 2015;2015:574832.
   PubMed Web of Science ®Google Scholar
• Garzon R, Calin GA, Croce CM. MicroRNAs in cancer[J]. Annu Rev Med. 2009;60(1):167–179.
   PubMed Web of Science ®Google Scholar
• Wojciechowska A, Braniewska A, Kozar-Kamiå Ska K. MicroRNA in cardiovascular biology and disease[J]. Adv Clin Exp Med. 2017;26(5):865–874.
   PubMed Web of Science ®Google Scholar
• Rottiers V, Näär AM. MicroRNAs in metabolism and metabolic disorders[J]. Nat Rev Mol Cell Biol. 2012;13(4):239–250.
   PubMed Web of Science ®Google Scholar
• Huang Y, Yan Y, Xv W, et al. A new insight into the roles of MiRNAs in metabolic syndrome[J]. Biomed Res Int. 2018;2018:1–15.
   Web of Science ®Google Scholar
• Zhang H, Feng Z, Huang R, et al. MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1[J]. Int J Oncol. 2014;45(5):2143–2152.
   PubMed Web of Science ®Google Scholar
• Zhang M, Sun W, Zhou M, et al. MicroRNA-27a regulates hepatic lipid metabolism and alleviates NAFLD via repressing FAS and SCD1[J]. Sci Rep. 2017;7(1):14493.
   PubMedGoogle Scholar
• Nie H, Song C, Wang D, et al. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR[J]. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2017;1863(12):3087–3094.
   PubMed Web of Science ®Google Scholar
• He S, Guo W, Deng F, et al. Targeted delivery of microRNA 146b mimic to hepatocytes by lactosylated PDMAEMA nanoparticles for the treatment of NAFLD[J]. Artif Cells Nanomed Biotechnol. 2018;46(sup2):217–228.
   PubMed Web of Science ®Google Scholar
• Lakhani HV, Sharma D, Dodrill MW, et al. Phenotypic alteration of hepatocytes in non-alcoholic fatty liver disease[J]. Int J Med Sci. 2018;15(14):1591–1599.
   PubMed Web of Science ®Google Scholar
• Vidal-Puig A, Jimenez-Li An M, Lowell BB, et al. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents[J]. J Clin Investig. 1996;97(11):2553.
   PubMed Web of Science ®Google Scholar
• Shimano H, Horton JD, Shimomura I, et al. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells [J]. J Clin Investig. 1997;99(5):846–854.
   PubMed Web of Science ®Google Scholar
• Koo SH. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis[J]. Clin Mol Hepatol. 2013;19(3):210–215.
   PubMedGoogle Scholar
• X D L, X M L, Gu JW, et al. MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway[J]. Eur Rev Med Pharmacol Sci. 2017;21(22):5153.
   PubMed Web of Science ®Google Scholar
• Shouda T, Yoshida T, Hanada T, et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis.[J]. J Clin Investig. 2001;108(12):1781–1788.
   PubMed Web of Science ®Google Scholar
• Soraya T, Mélissa R, Bhama R, et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis.[J]. J Exp Med. 2009;206(10):2067–2077.
   PubMed Web of Science ®Google Scholar
• Paul K, Howard JK, Badman MK, et al. Enhanced leptin sensitivity and improved glucose homeostasis in mice lacking suppressor of cytokine signaling-3 in POMC-expressing cells[J]. Cell Metab. 2006;4(2):123–132.
   PubMed Web of Science ®Google Scholar
• Marina L, Kurkowski MU, Katharina L, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer[J]. Cancer Cell. 2011;19(4):441–455.
   PubMed Web of Science ®Google Scholar
• Kohjiro U, Tatsuya K, Yu-Hua T, et al. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse[J]. Proc Natl Acad Sci U S A. 2004;101(28):10422–10427
   PubMed Web of Science ®Google Scholar
• Pan X, Wang P, Luo J, et al. Adipogenic changes of hepatocytes in a high-fat diet-induced fatty liver mice model and non-alcoholic fatty liver disease patients[J]. Endocrine. 2015;48(3):834–847.
   PubMed Web of Science ®Google Scholar
• Liu Z, Gan L, Zhou Z, et al. SOCS3 promotes inflammation and apoptosis via inhibiting JAK2/STAT3 signaling pathway in 3T3-L1 adipocyte[J]. Immunobiology. 2015;220(8):947–953.
   PubMed Web of Science ®Google Scholar